XOMA Royalty (XOMA) Interest Coverage Ratio Growth (1y) (2012 - 2026)
XOMA Royalty (XOMA) Interest Coverage Ratio Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - | -60.44% |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - | -347.04% |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn | 787.12% |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn | 53.59% |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn | -32.04% |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn | 1,378.45% |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | -102.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -102.34% |
| Jun 30, 2025 | 149.35% |
| Mar 31, 2025 | 150.00% |
| Dec 31, 2024 | 95.56% |
| Sep 30, 2024 | 9.14% |
| Jun 30, 2024 | -13.89% |
| Mar 31, 2024 | 83.66% |
| Dec 31, 2023 | 60.46% |
| Sep 30, 2023 | -100.21% |
| Jun 30, 2023 | -75.45% |
| Mar 31, 2023 | 72.55% |
| Dec 31, 2022 | -119.65% |
| Sep 30, 2022 | -155.16% |
| Jun 30, 2022 | -221.14% |
| Mar 31, 2022 | -85.71% |
| Dec 31, 2021 | 24.60% |
| Sep 30, 2021 | 7.90% |
| Jun 30, 2021 | 52.29% |
| Mar 31, 2021 | -114.63% |
| Dec 31, 2020 | 8,229.37% |